Form 4 for EW Edwards Lifesciences
Accepted 2022-02-08 00:00:00 ET · period of report 2022-02-08 · accession 0001225208-22-001657 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-08 | 2022-02-08 | EW | GALLAHUE KIERAN | Dir | S - Sale+OE | $110.79 | -32.3K | 3,433 | -90% | -$3.57M |
| D | 2022-02-08 | 2022-02-08 | EW | GALLAHUE KIERAN | Dir | M - OptEx | $22.29 | +32.3K | 35.7K | +940% | +$719.0K |
| D | 2022-02-08 | 2022-02-08 | EW | GALLAHUE KIERAN | Dir | M - OptEx | $0.00 | -32.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-08 | S | D | 32,256 | $110.79 | 3,433 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $110.50 to $111.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2022-02-08 | M | A | 32,256 | $22.29 | 35,689 | D | — | — | |
| 3 | Derivative | Director Stock Option (Right to Acquire) | 2022-02-08 | M | D | 32,256 | $0.00 | 0 | D | $22.29 · 2016-02-19 to 2022-02-18 | 32,256 Common Stock |